AstraZeneca's stock has surged by 137% over the last 120 days, attracting attention from analysts and investors, including Jim Cramer. The company's oncology segment, which has generated $25.6 billion and boasts 16 blockbuster drugs, is driving optimism for future growth. However, AstraZeneca is under scrutiny due to potential UK policy headwinds and an ongoing investigation in China, leading Cramer to advise caution despite the company's ambitious plans to raise revenue to $80 billion by 2030.
“CNBC’s Jim Cramer explains why he is keeping an eye on shares of AstraZeneca.”
“AstraZeneca PLC (NASDAQ: AZN) is one of the stocks in focus on Jim Cramer’s game plan.”
“I think AstraZeneca has got a better portfolio at this very moment.”
“AstraZeneca is the perfect vehicle for this rotation. Its stock has already priced in the optimism, surging 137% over the last 120 days.”
“the segment grew [14% to $25.6 billion], fueled by two blockbuster drugs.”
“CEO Pascal Soriot highlighted that AstraZeneca announced the results of 16 positive Phase 3 studies during the year and now has 16 blockbuster medicines.”
“Aight, the argument’s all 'AstraZeneca’s pipeline’s golden!' but y’all ignore how UK policy headwinds and that 137% run make it one earnings miss away from a freefall...”
“AstraZeneca’s pipeline’s golden!' but y’all ignore how UK policy headwinds...”
“How does AstraZeneca's pipeline impact its stock price?”
“What are the key risks associated with investing in AstraZeneca?”
“AstraZeneca CEO Pascal Soriot explained in a Tuesday interview with CNBC's Jim Cramer why the drugmaker believes it can almost double revenue by 2030.”
“CNBC’s Jim Cramer explains why he is keeping an eye on shares of AstraZeneca.”
